Dopaminergic pathway modulation

Dopaminergic pathway modulation refers to the regulation and alteration of dopamine signaling in the nervous system. The dopaminergic system involves multiple interconnected pathways including the mesolimbic, mesocortical, nigrostriatal, and tuberoinfundibular pathways. These pathways consist of dopaminergic neurons that synthesize and release dopamine, which then binds to five types of G protein-coupled dopamine receptors (D1-D5). The receptors are divided into two families: D1-like receptors (D1 and D5) that stimulate adenylyl cyclase and increase cAMP production, and D2-like receptors (D2, D3, and D4) that inhibit adenylyl cyclase and decrease cAMP levels. Dopamine release occurs through two main mechanisms: phasic transmission (fast, transient release driven by action potentials) and tonic transmission (slower, sustained release independent of presynaptic action potentials). Modulation of these pathways affects diverse physiological functions including motor control, reward processing, cognition, emotion, and neuroendocrine regulation. The dopaminergic system is critically involved in multiple neurological and psychiatric conditions, and dysfunction in specific pathways contributes to diseases such as Parkinson's disease, schizophrenia, ADHD, and addiction. Therapeutic modulation of dopaminergic pathways can involve targeting specific receptors, altering dopamine synthesis or reuptake, or modifying downstream signaling cascades involving PKA, DARPP-32, and other effector molecules.

Other names

Dopamine pathway modulationDopaminergic signaling modulationDopamine system modulationDopaminergic neurotransmission modulation

Dopamine receptor agonism (D1-like receptors coupled to Gαs/olf protein increase cAMP levels via adenylyl cyclase activation), Dopamine receptor antagonism (D2-like receptors coupled to Gαi/o protein inhibit adenylyl cyclase and decrease cAMP levels), Modulation of dopamine transporter (DAT) activity affecting reuptake, Modulation of phasic versus tonic dopamine release, Phospholipase C (PLC) pathway activation, Protein kinase A (PKA) pathway modulation, DARPP-32 mediated signaling amplification